Craig B. Reynolds Sells 40,000 Shares of Masimo Co. (NASDAQ:MASI) Stock

Masimo Co. (NASDAQ:MASI) Director Craig B. Reynolds sold 40,000 shares of the company’s stock in a transaction on Friday, April 26th. The shares were sold at an average price of $136.17, for a total value of $5,446,800.00. Following the transaction, the director now directly owns 7,406 shares in the company, valued at approximately $1,008,475.02. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Masimo Stock Performance

Shares of MASI stock opened at $134.01 on Thursday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.22 and a current ratio of 2.18. Masimo Co. has a fifty-two week low of $75.22 and a fifty-two week high of $189.30. The stock has a 50 day moving average price of $135.90 and a two-hundred day moving average price of $117.70. The company has a market capitalization of $7.09 billion, a P/E ratio of 88.75 and a beta of 0.97.

Masimo (NASDAQ:MASI) last announced its quarterly earnings data on Tuesday, February 27th. The medical equipment provider reported $1.25 earnings per share for the quarter, beating the consensus estimate of $0.82 by $0.43. Masimo had a return on equity of 13.77% and a net margin of 3.98%. The firm had revenue of $548.90 million during the quarter, compared to the consensus estimate of $545.69 million. During the same quarter in the previous year, the company posted $1.32 earnings per share. The business’s revenue was down 11.0% on a year-over-year basis. Analysts expect that Masimo Co. will post 3.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on MASI shares. BTIG Research increased their price objective on Masimo from $145.00 to $166.00 and gave the stock a “buy” rating in a report on Monday, March 25th. StockNews.com raised Masimo from a “sell” rating to a “hold” rating in a report on Friday, March 29th. Piper Sandler increased their price objective on Masimo from $70.00 to $117.00 and gave the stock a “neutral” rating in a report on Monday, February 26th. Stifel Nicolaus raised Masimo from a “hold” rating to a “buy” rating and increased their price objective for the stock from $148.00 to $170.00 in a report on Monday, April 15th. Finally, Wells Fargo & Company raised Masimo from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $117.00 to $160.00 in a report on Monday, March 25th. Five analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, Masimo presently has an average rating of “Hold” and a consensus price target of $137.43.

Institutional Trading of Masimo

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Riverview Trust Co bought a new stake in Masimo in the first quarter valued at approximately $25,000. Massmutual Trust Co. FSB ADV raised its holdings in shares of Masimo by 140.6% during the fourth quarter. Massmutual Trust Co. FSB ADV now owns 243 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 142 shares in the last quarter. Byrne Asset Management LLC bought a new position in shares of Masimo during the fourth quarter valued at approximately $28,000. NBC Securities Inc. bought a new position in shares of Masimo during the third quarter valued at approximately $34,000. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of Masimo by 851.6% during the fourth quarter. EverSource Wealth Advisors LLC now owns 295 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 264 shares in the last quarter. Institutional investors own 85.96% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.